Advaxis Kick Starts Early-Stage Study For Prostate Cancer Immunotherapy

by Vandana Singh, Benzinga Editor

July 15, 2021 8:53 AM | 1 min read |

Advaxis Inc ADXS has initiated a Phase 1 study evaluating ADXS-504 in patients with recurrent prostate cancer.
The study, being conducted at Columbia University Irving Medical Center, is the first clinical evaluation of ADXS-504, Advaxis' off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer.
The Phase 1 open-label dose-escalation study will evaluate the safety and tolerability of two dose levels of ADXS-504 monotherapy.
The study will also evaluate preliminary clinical and immune responses following treatment with ADXS-504 monotherapy.
Recently, the Company has announced a reverse merger agreement with privately-held Biosight Ltd.
Price Action: ADXS shares are up 3.7% at $0.45 during the premarket session on the last check Thursday.

Posted In: Biotech News Penny Stocks Health Care General Briefs Phase 1 Trial prostate cancer

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.